JAMA Intern Med:对于老年糖尿病患者,非强化治疗未尝不是一件好事

2015-10-28 崔倩 译 MedSci原创

接受治疗的老年糖尿病患者,其血压(BP)或血糖水平有潜在的较低的危险很少进行非强化治疗。由于建立了低血压和血糖的风险,这是一个减少药物的伤害重大的机会。 该研究的目的是研究在中老年1型或2型糖尿病患者中,非强化降BP和降血糖药的概率,这些患者可能接受过度治疗率。该回顾性队列研究使用美国退伍军人健康管理局的数据。参加者包括211667名70岁以上正在接受积极治疗的糖尿病患者(定义为降血压药物而不是血

接受治疗的老年糖尿病患者,其血压(BP)或血糖水平有潜在的较低的危险,且很少进行非强化治疗。低血压和血糖的明确风险的制定是一个减少药物的伤害重大的机会。 该研究的目的是研究在中老年1型或2型糖尿病患者中,非强化降BP和降血糖药的概率,这些患者可能接受的过度治疗率。

该回顾性队列研究使用美国退伍军人健康管理局的数据。参加者包括211667名70岁以上正在接受积极治疗的糖尿病患者(定义为降血压药物治疗,而不是血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂,也不是盐酸二甲双胍等降糖药等),该研究在2012年1月1日至12月31日进行,数据分析在2013年12月10日和2015年7月20日之间进行。

如果患者有低血压,或在他们在2012年最后一次测量的血红蛋白A1c(HbA1c)水平较低,则参加者有资格获得非强化治疗。研究人员定义非常低的BP为小于120/65mm Hg,适度低为收缩压为120至129mm Hg或舒张压(DBP)低于65mm Hg,非常低的HbA1c为小于6.0%,和适度低的HbA1c为6.0%至6.4%。所有其他值都不能算低。

干预措施为药物非强化治疗,定义为指数测量后6个月内停药或减少剂量。

在积极治疗BP组有211667位参与者,超过一半人有中度或非常低的血压水平。在血压水平不低的104486患者中,15.1%的治疗未被强化。在血压水平中度低的25955例患者中,16.0%的治疗未被强化。在81226例具有非常低的血压水平的患者中,18.8%接受BP药物非强化治疗。在治疗未被强化且具有非常低的血压水平的患者中,只有0.2%的患者在后续血压测量中显示升高(BP≥140/90mm Hg)。在积极治疗的HbA1c组有179991人参加。143305患者的HbA1c水平不是很低,17.5%的治疗未被强化。23769例中等偏低的HbA1c水平患者中,20.9%的患者治疗未被强化。在12917例极低的HbA1c水平患者中,27.0%接受药物非强化治疗。在具有非常低的HbA1c水平的治疗未被强化的患者中,少于0.8%的患者后续测量的HbA1c水平升高(≥7.5%)。

在治疗造成了非常低的HbA1c或BP水平的老年患者中,27%或更少的患者接受了非强化治疗,这代表失去了一个减少过度治疗的机会。较低的HbA1c或BP水平或低预期寿命与未强化治疗有点关联。实践指导方针和措施的表现应该把更多的精力放在通过非强化治疗来减少过度治疗。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=57136, encodeId=87925e13652, content=给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 23:45:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42276, encodeId=a177422e690, content=因人而异, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Nov 02 14:29:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42277, encodeId=a498422e7e6, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Nov 02 14:29:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473909, encodeId=848e14e39098a, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479518, encodeId=7be114e951823, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bf97540688, createdName=ms3323097325231039, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554069, encodeId=5b4b155406959, content=<a href='/topic/show?id=394d5013059' target=_blank style='color:#2F92EE;'>#强化治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50130, encryptionId=394d5013059, topicName=强化治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcc714501479, createdName=huanbaofeng, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606679, encodeId=847e16066e903, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41870, encodeId=94d8418e0b9, content=很难, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c171373773, createdName=gzhjjx, createdTime=Thu Oct 29 11:59:00 CST 2015, time=2015-10-29, status=1, ipAttribution=)]
    2016-01-13 Lynee劲飞扬

    给力

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=57136, encodeId=87925e13652, content=给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 23:45:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42276, encodeId=a177422e690, content=因人而异, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Nov 02 14:29:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42277, encodeId=a498422e7e6, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Nov 02 14:29:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473909, encodeId=848e14e39098a, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479518, encodeId=7be114e951823, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bf97540688, createdName=ms3323097325231039, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554069, encodeId=5b4b155406959, content=<a href='/topic/show?id=394d5013059' target=_blank style='color:#2F92EE;'>#强化治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50130, encryptionId=394d5013059, topicName=强化治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcc714501479, createdName=huanbaofeng, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606679, encodeId=847e16066e903, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41870, encodeId=94d8418e0b9, content=很难, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c171373773, createdName=gzhjjx, createdTime=Thu Oct 29 11:59:00 CST 2015, time=2015-10-29, status=1, ipAttribution=)]
    2015-11-02 nizongzan

    因人而异

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=57136, encodeId=87925e13652, content=给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 23:45:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42276, encodeId=a177422e690, content=因人而异, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Nov 02 14:29:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42277, encodeId=a498422e7e6, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Nov 02 14:29:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473909, encodeId=848e14e39098a, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479518, encodeId=7be114e951823, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bf97540688, createdName=ms3323097325231039, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554069, encodeId=5b4b155406959, content=<a href='/topic/show?id=394d5013059' target=_blank style='color:#2F92EE;'>#强化治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50130, encryptionId=394d5013059, topicName=强化治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcc714501479, createdName=huanbaofeng, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606679, encodeId=847e16066e903, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41870, encodeId=94d8418e0b9, content=很难, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c171373773, createdName=gzhjjx, createdTime=Thu Oct 29 11:59:00 CST 2015, time=2015-10-29, status=1, ipAttribution=)]
    2015-11-02 nizongzan

    收藏

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=57136, encodeId=87925e13652, content=给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 23:45:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42276, encodeId=a177422e690, content=因人而异, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Nov 02 14:29:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42277, encodeId=a498422e7e6, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Nov 02 14:29:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473909, encodeId=848e14e39098a, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479518, encodeId=7be114e951823, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bf97540688, createdName=ms3323097325231039, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554069, encodeId=5b4b155406959, content=<a href='/topic/show?id=394d5013059' target=_blank style='color:#2F92EE;'>#强化治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50130, encryptionId=394d5013059, topicName=强化治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcc714501479, createdName=huanbaofeng, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606679, encodeId=847e16066e903, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41870, encodeId=94d8418e0b9, content=很难, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c171373773, createdName=gzhjjx, createdTime=Thu Oct 29 11:59:00 CST 2015, time=2015-10-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=57136, encodeId=87925e13652, content=给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 23:45:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42276, encodeId=a177422e690, content=因人而异, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Nov 02 14:29:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42277, encodeId=a498422e7e6, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Nov 02 14:29:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473909, encodeId=848e14e39098a, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479518, encodeId=7be114e951823, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bf97540688, createdName=ms3323097325231039, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554069, encodeId=5b4b155406959, content=<a href='/topic/show?id=394d5013059' target=_blank style='color:#2F92EE;'>#强化治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50130, encryptionId=394d5013059, topicName=强化治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcc714501479, createdName=huanbaofeng, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606679, encodeId=847e16066e903, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41870, encodeId=94d8418e0b9, content=很难, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c171373773, createdName=gzhjjx, createdTime=Thu Oct 29 11:59:00 CST 2015, time=2015-10-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=57136, encodeId=87925e13652, content=给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 23:45:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42276, encodeId=a177422e690, content=因人而异, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Nov 02 14:29:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42277, encodeId=a498422e7e6, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Nov 02 14:29:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473909, encodeId=848e14e39098a, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479518, encodeId=7be114e951823, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bf97540688, createdName=ms3323097325231039, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554069, encodeId=5b4b155406959, content=<a href='/topic/show?id=394d5013059' target=_blank style='color:#2F92EE;'>#强化治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50130, encryptionId=394d5013059, topicName=强化治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcc714501479, createdName=huanbaofeng, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606679, encodeId=847e16066e903, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41870, encodeId=94d8418e0b9, content=很难, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c171373773, createdName=gzhjjx, createdTime=Thu Oct 29 11:59:00 CST 2015, time=2015-10-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=57136, encodeId=87925e13652, content=给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 23:45:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42276, encodeId=a177422e690, content=因人而异, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Nov 02 14:29:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42277, encodeId=a498422e7e6, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Nov 02 14:29:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473909, encodeId=848e14e39098a, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479518, encodeId=7be114e951823, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bf97540688, createdName=ms3323097325231039, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554069, encodeId=5b4b155406959, content=<a href='/topic/show?id=394d5013059' target=_blank style='color:#2F92EE;'>#强化治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50130, encryptionId=394d5013059, topicName=强化治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcc714501479, createdName=huanbaofeng, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606679, encodeId=847e16066e903, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41870, encodeId=94d8418e0b9, content=很难, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c171373773, createdName=gzhjjx, createdTime=Thu Oct 29 11:59:00 CST 2015, time=2015-10-29, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=57136, encodeId=87925e13652, content=给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 23:45:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42276, encodeId=a177422e690, content=因人而异, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Nov 02 14:29:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42277, encodeId=a498422e7e6, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Nov 02 14:29:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473909, encodeId=848e14e39098a, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479518, encodeId=7be114e951823, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bf97540688, createdName=ms3323097325231039, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554069, encodeId=5b4b155406959, content=<a href='/topic/show?id=394d5013059' target=_blank style='color:#2F92EE;'>#强化治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50130, encryptionId=394d5013059, topicName=强化治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcc714501479, createdName=huanbaofeng, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606679, encodeId=847e16066e903, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 29 23:09:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41870, encodeId=94d8418e0b9, content=很难, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c171373773, createdName=gzhjjx, createdTime=Thu Oct 29 11:59:00 CST 2015, time=2015-10-29, status=1, ipAttribution=)]
    2015-10-29 gzhjjx

    很难

    0

相关资讯

Front Aging Neurosci:老年缺血性卒中患者,女性预后更差

背景:尽管在男性卒中的发生率和死亡率较高,但卒中对女性有着更大的临床影响。然而,在老年卒中患者中的性别差异尚不清楚。因此,研究人员旨在评估老年卒中患者的性别差异。方法:研究人员招募了中国天津神经专科医院2005年到2013年期间1484名急性缺血性卒中(AIS)患者(大于75岁)。记录患者的卒中类型,严重程度,危险因素,以及卒中后3个月和12个月预后。结果:与男性患者相比,女性患者发生严重卒中(1

科学研究给老年的全新定义:60岁只是中年

据科学日报报道,根据发表在期刊《公共科学图书馆·综合》上的一项最新研究,寿命的快速增长并不一定会导致人群快速衰老。这项反直觉的发现产生于将国际应用系统分析研究所(International Institute of AppliedSystem Analysis,简称IIASA)提出的对衰老的最新测量应用于截止2050年未来欧洲人口预测问题上。寿命的快速增长并不一定会导致人群快速衰老。“年龄可以被定

Surgery:为什么早期胰腺癌的老年患者手术率那么低?

对于早期胰腺癌患者,尽早的手术治疗可以显著患者的健康治疗和临床结局,但历史数据显示该类患者的手术比例很低。研究者进行了一项基于人群的回顾性研究,欲探究该类患者有哪些因素会影响到手术的选择。研究者纳入了2001年1月1日-2009年12月31日的年龄≥66岁的早期小范围局部的胰腺癌患者,通过德州癌症数据以及相关医疗数据收集与手术切除相关的潜在影响因素。通过多因素回归模型和Cox风险比例模型对变量和数

J Affect Disord:血浆低维生素D浓度与老年抑郁症状相关

背景:这篇研究旨在确定血浆25羟维生素D的浓度和韩国老年任抑郁症的相关性。方法:这篇研究应用来自于韩国城市农村老年人研究中的数据,共招募2942名年龄在65岁以上的城市和农村人口。排除抗抑郁药治疗的患者,研究者对2853名受试者(962名为男性,1891名女性)进行分析。血浆25羟维生素D作为连续分类变量进行分析。应用韩国老年抑郁简明量表进行抑郁症状的评估。应用多变量logistic回归分析男性和

AJCN:维生素B12或并不能改善老年个体的认知功能

近日,一项刊登于国际杂志the American Journal of Clinical Nutrition上的研究论文中,来自伦敦卫生和热带医学院的研究人员通过研究表示,维生素B12补充剂或许对机体中度缺乏B12的老年个体的认知和神经功能并无任何益处。在英国75岁以上的老年人中,大约六分之一的个体都存在机体维生素B12缺乏的情况,当维生素B12缺乏严重时就会引发个体神经系统出现明显的问题,比如肌

ONF:对老年癌症患者如何诊断抑郁症?疲劳状态帮到你

目的:该研究的目的在于探究疲惫的程度是否可以作为调查老年癌症患者抑郁的一项指标。方式:该研究为横断面、观察性、队列研究。研究地点在比利时和荷兰等共七家医院进行。参与研究的人员为205位老年癌症患者和436位未患癌症的老年患者,且参与人员平均年龄超过70岁。通过利用老人疲劳状态评估老年抑郁的灵敏性、特异性和预测价值,来判断根据老人疲劳程度诊断抑郁症的准确性。实验观察的主要指标是老人疲劳程度(通过视觉